+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Gaucher's disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Gaucher's disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Fabry Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Fabry Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Palmar Hyperhidrosis - Epidemiology Forecast to 2032 (US) - Product Thumbnail Image

Palmar Hyperhidrosis - Epidemiology Forecast to 2032 (US)

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Hunter Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hunter Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Metabolic Acidosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Metabolic Acidosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Osteoporosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Osteoporosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Dementia with Diabetes - Epidemiology Forecast to 2032 - Product Thumbnail Image

Dementia with Diabetes - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Pompe Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Pompe Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Cushing's Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Cushing's Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Diabetic Retinopathy - Epidemiology Forecast to 2032 - Product Thumbnail Image

Diabetic Retinopathy - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Hypoparathyroidism - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hypoparathyroidism - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Somatotropin - Biosimilar Insight, 2022 - Product Thumbnail Image

Somatotropin - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Insulin Glargine- - Biosimilar Insight, 2022 - Product Thumbnail Image

Insulin Glargine- - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Acromegaly - Epidemiology Forecast to 2032 - Product Thumbnail Image

Acromegaly - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more